Efficacies of topical formulations of foscarnet and acyclovir and of 5- percent acyclovir ointment (Zovirax) in a murine model of cutaneous herpes simplex virus type 1 infection

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 1, 2000, Pages 30-38

  Piret, Jocelyne ^a   Désormeaux, André ^a   Gourde, Pierrette ^a   Juhász, Julianna ^b   Bergeron, Michel G ^a,c  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FOSCARNET; POLOXAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG SCREENING; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; MOUSE; NONHUMAN; OINTMENT; PRIORITY JOURNAL;

EID: 0033987077     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.1.30-38.2000     Document Type: Article

References (37)

1. Alenius, S., M. Berg, F. Froberg, K. Eklind, B. Lindborg, and B. Öberg. 1982. Therapeutic effects of foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 in guinea pigs. J. Infect. Dis. 146: 569-573.
2. Barton, S. E., P. E. Munday, G. R. Kinghorn, W. I. van der Meijden, E. Stolz, A. Notowicz, S. Rashid, J. L. Schuller, A. J. Essex-Cater, M. H. M. Kuijpers, and A. C. Chanas. 1986. Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study. Genitourin. Med. 62:247-250.
3. Blyth, W. A., D. A. Harbour, and T. J. Hill. 1984. Pathogenesis of zosteriform spread of herpes simplex virus in the mouse. J. Gen. Virol. 65:1477-1485.
4. Chatis, P. A., C. H. Miller, L. E. Schrager, and C. S. Crumpacker. 1989. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N. Engl. J. Med. 320:297-300.
5. Chrisp, P., and P. Clissold. 1991. Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41:104-129.
6. Corey, L., A. J. Nahmias, M. E. Guinan, J. K. Benedetti, C. W. Critchlow, and K. K. Holmes. 1982. A trial of topical acyclovir in genital herpes simplex virus infections. N. Engl. J. Med. 306:1313-1319.
7. Descamps, J., E. De Clercq, P. J. Barr, A. S. Jones, R. T. Walker, P. F. Torrence, and D. Shugar. 1979. Relative potenties of different antiherpes agents in the topical treatment of cutaneous herpes simplex virus infection of athymic nude mice. Antimicrob. Agents Chemother. 16:680-682.
8. Dusserre, N., C. Lessard, N. Paquette, S. Perron, L. Poulin, M. Tremblay, D. Beauchamp, A. Désormeaux, and M. G. Bergeron. 1995. Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution, and pharmacokinetics. AIDS 9:833-841.
9. Englund, J. A., M. E. Zimmerman, E. M. Swierkosz, J. L. Goodman, D. R. Scholl, and H. H. Balfour. 1990. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann. Intern. Med. 112:416-422.
10. Erlich, K. S., M. A. Jacobson, J. E. Koehler, S. E. Follansbee, D. P. Drennan, L. Gooze, S. Safrin, and J. Mills. 1989. Foscarnet therapy for severe acyclovir-resistant herpes virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. Ann. Intern. Med. 110:710-713.
11. Ijichi, K., N. Ashida, S. Varia, and H. Machida. 1993. Topical treatment with BV-araU of immunosuppressed and immunocompetent shaved mice cutaneously infected with herpes simplex virus type 1. Antiviral Res. 21:47-57.
12. Juhász, J., S. Mahashabde, and J. Sequeira. 1996. Comparison of in vitro release rates of nitroglycerin by diffusion through a Teflon membrane to the USP method. Drug Dev. Ind. Pharm. 22:1139-1144.
13. Kost, R. G., E. L. Hill, M. Tigges, and S. E. Strauss. 1993. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N. Engl. J. Med. 329:1777-1782.
14. Kristofferson, A., A.-C. Ericson, A. Sohl-Åkerlund, and R. Datema. 1988. Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease. J. Gen. Virol. 69:1157-1166.
15. Lee, P. H., M. H. Su, E. R. Kern, and W. I. Higuchi. 1992. Novel animal model for evaluating topical efficacy of antiviral agents: flux versus efficacy correlations in the acyclovir treatment of cutaneous herpes simplex virus type 1 (HVS-1) infections in hairless mice. Pharm. Res. 9:979-989.
16. Ljungman, P., M. N. Ellis, K. C. Hackman, D. H. Shepp, and J. D. Meyers. 1990. Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J. Infect. Dis. 162:244-248.
17. Lobe, D. C., T. Spector, and N. Ellis. 1991. Synergistic topical therapy by acyclovir and A1110U for herpes simplex virus induced zosteriform rash in mice. Antiviral Res. 15:87-100.
18. Luby, J. P., J. W. Gnann, W. J. Alexander, V. A. Hatcher, A. E. Friedman-Kien, R. J. Klein, H. Keyserling, A. Nahmias, J. Mills, J. Schachter, J. M. Douglas, L. Corey, and S. L. Sacks. 1984. A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo. J. Infect. Dis. 150:1-6.
19. Manickan, E., and B. T. Rouse. 1995. Roles of different T-cell subsets in control of herpes simplex virus infection determined by using T-cell-deficient mouse models. J. Virol. 69:8178-8179.
20. Öberg, B. 1989. Antiviral effects of phosphonoformate. Pharmacol. Ther. 19: 387-415.
21. Piret, J., P. Gourde, H. Cormier, A. Désormeaux, D. Beauchamp, M. J. Tremblay, J. Juhász, and M. G. Bergeron. 1999. Efficacy of gel formulations containing free or liposomal foscarnet in a murine model of cutaneous herpes simplex type-1 infection. J. Liposome Res. 9:181-198.
22. Reichman, R. C., G. J. Badger, M. E. Guinan, A. J. Nahmias, R. E. Keeney, L. G. Davis, T. Ashikaga, and R. Dolin. 1983. Topically administered acyclovir in the treatment of recurrent herpes simplex genitalis: a controlled trial. J. Infect. Dis. 147:336-340.
23. Roizman, B., and A. E. Sears. 1990. Herpes simplex viruses and their replication, p. 1795-1841. In B. N. Fields, D. M. Knipe, R. M. Chanock, M. S. Hirsch, J. L. Melnick, T. P. Monath, and B. Roizman (ed.), Fields virology, vol. 1. Raven Press, New York, N. Y.
24. Sacks, S. L., J. Portnoy, D. Lawee, W. Schlech, F. Y. Aoki, D. L. Tyrrell, M. Poisson, C. Bright, and J. Kaluski. 1987. Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial. J. Infect. Dis. 155:178-186.
25. Safrin, S., T. Assaykeen, S. Follansbee, and J. Mills. 1990. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J. Infect. Dis. 161:1078-1084.
26. Safrin, S., T. G. Berger, I. Gilson, P. R. Wolfe, C. B. Wolfsy, J. Mills, and K. K. Biron. 1991. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann. Intern. Med. 115:19-21.
27. Safrin, S., C. Crumpacker, P. Chatis, R. Davis, R. Hafner, J. Rush, H. A. Kessler, B. Landry, and J. Mills. 1991. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N. Engl. J. Med. 325:551-555.
28. Safrin, S., S. Kemmerly, B. Plotkin, T. Smith, N. Weissbach, D. De Veranez, L. D. Phan, and D. Conn. 1994. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J. Infect. Dis. 169:193-196.
29. Simmons, A., and A. A. Nash. 1984. Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent disease. J. Virol. 52:816-821.
30. Spruance, S. L., and C. S. Crumpacker. 1982. Topical 5 percent acyclovir in polyethylene glycol for herpes simplex labialis: antiviral effect without clinical benefit. Am. J. Med. 73:315-319.
31. Spruance, S. L., and D. J. Freeman. 1990. Topical treatment of cutaneous herpes simplex virus infections. Antiviral Res. 14:305-321.
32. Spruance, S. L., T. L. Rea, C. Thoming, R. Tucker, R. Saltzman, and R. Boon. 1997. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. JAMA 277:1374-1379.
33. Verdonck, L. F., J. J. Cornelissen, J. Smit, J. Lepoutre, G. C. de Gast, A. W. Dekker, and M. Rozenberg-Arska. 1993. Successful foscarnet therapy for acyclovir-resistant mucocutaneous infection with herpes simplex virus in a recipient of allogeneic BMT. Bone Marrow Transplant. 11:177-179.
34. Wallin, J., J. O. Lemestedt, S. Ogenstad, and E. Lycke. 1985. Topical treatment of recurrent genital herpes infections with foscarnet. Scand. J. Infect. Dis. 17:165-172.
35. Walters, K. A. 1989. Penetration enhancers and their use in transdermal therapeutic systems, p. 197-245. In J. Hadgraft and R. H. Guy (ed.), Transdermal drug delivery: developmental issues and research initiatives, vol. 35. Marcel Dekker, Inc., New York, N.Y.
36. Whitley, R. J. 1990. Herpes simplex viruses, p. 1843-1887. In B. N. Fields, D. M. Knipe, R. M. Chanock, M. S. Hirsch, J. L. Melnick, T. P. Monath, and B. Roizman (ed.), Fields virology, vol. 1. Raven Press, New York, N.Y.
37. Wu, S. T., G. K. Shiu, J. E. Simmons, R. L. Bronaugh, and J. P. Skelly. 1992. In vitro release of nitroglycerin from topical products by use of artificial membranes. J. Pharm. Sci. 81:1153-1156.